278 related articles for article (PubMed ID: 22738946)
1. Colchicine is a safe drug in children with familial Mediterranean fever.
Padeh S; Gerstein M; Berkun Y
J Pediatr; 2012 Dec; 161(6):1142-6. PubMed ID: 22738946
[TBL] [Abstract][Full Text] [Related]
2. An overview of familial Mediterranean fever with emphasis on pyrin and colchicine.
Dbouk HA; Uthman IW
J Med Liban; 2008; 56(1):35-41. PubMed ID: 19534089
[TBL] [Abstract][Full Text] [Related]
3. Discontinuing colchicine in symptomatic carriers for MEFV (Mediterranean FeVer) variants.
Sönmez HE; Batu ED; Bilginer Y; Özen S
Clin Rheumatol; 2017 Feb; 36(2):421-425. PubMed ID: 27679472
[TBL] [Abstract][Full Text] [Related]
4. [Familial Mediterranean fever].
Georgin-Lavialle S; Hentgen V; Stankovic Stojanovic K; Bachmeyer C; Rodrigues F; Savey L; Abbara S; Conan PL; Fraisse T; Delplanque M; Rouet A; Sbeih N; Koné-Paut I; Grateau G
Rev Med Interne; 2018 Apr; 39(4):240-255. PubMed ID: 29526329
[TBL] [Abstract][Full Text] [Related]
5. MEFV gene compound heterozygous mutations in familial Mediterranean fever phenotype: a retrospective clinical and molecular study.
Caglayan AO; Demiryilmaz F; Ozyazgan I; Gumus H
Nephrol Dial Transplant; 2010 Aug; 25(8):2520-3. PubMed ID: 19934083
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous necrotizing vasculitis as a manifestation of familial Mediterranean fever.
Komatsu S; Honma M; Igawa S; Tsuji H; Ishida-Yamamoto A; Migita K; Ida H; Iizuka H
J Dermatol; 2014 Sep; 41(9):827-9. PubMed ID: 25109905
[TBL] [Abstract][Full Text] [Related]
7. Age dependent safety and efficacy of colchicine treatment for familial mediterranean fever in children.
Goldberg O; Levinsky Y; Peled O; Koren G; Harel L; Amarilyo G
Semin Arthritis Rheum; 2019 Dec; 49(3):459-463. PubMed ID: 31255241
[TBL] [Abstract][Full Text] [Related]
8. Leucopenia resoluted with colchicine in familial mediterranean Fever.
Sakallioglu O
J Pediatr Hematol Oncol; 2012 Mar; 34(2):162. PubMed ID: 22031120
[No Abstract] [Full Text] [Related]
9. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever.
Kallinich T; Wittkowski H; Keitzer R; Roth J; Foell D
Ann Rheum Dis; 2010 Apr; 69(4):677-82. PubMed ID: 19762364
[TBL] [Abstract][Full Text] [Related]
10. Prevention of amyloidosis in familial Mediterranean fever with colchicine: a case-control study in Armenia.
Sevoyan MK; Sarkisian TF; Beglaryan AA; Shahsuvaryan GR; Armenian HK
Med Princ Pract; 2009; 18(6):441-6. PubMed ID: 19797919
[TBL] [Abstract][Full Text] [Related]
11. Familial Mediterranean fever in children and adolescents: factors for colchicine dosage and predicting parameters for dose increase.
Knieper AM; Klotsche J; Lainka E; Berger T; Dressler F; Jansson AF; Rietschel C; Oommen PT; Berendes R; Niehues T; Neudorf U; Foell D; Wittkowski H; Kallinich T
Rheumatology (Oxford); 2017 Sep; 56(9):1597-1606. PubMed ID: 28859329
[TBL] [Abstract][Full Text] [Related]
12. Relationship between response to colchicine treatment and MDR1 polymorphism in familial Mediterranean fever patients.
Uludag A; Silan C; Atik S; Akurut C; Uludag A; Silan F; Ozdemir O
Genet Test Mol Biomarkers; 2014 Feb; 18(2):73-6. PubMed ID: 24180297
[TBL] [Abstract][Full Text] [Related]
13. Familial Mediterranean fever in siblings.
Özçakar ZB; Erdogan BD; Elhan AH; Yalçinkaya F
J Rheumatol; 2012 Nov; 39(11):2170-4. PubMed ID: 23027888
[TBL] [Abstract][Full Text] [Related]
14. Colchicine treatment in children with familial Mediterranean fever.
Ozkaya N; Yalçinkaya F
Clin Rheumatol; 2003 Oct; 22(4-5):314-7. PubMed ID: 14579163
[TBL] [Abstract][Full Text] [Related]
15. Familial Mediterranean Fever.
Kucuk A; Gezer IA; Ucar R; Karahan AY
Acta Medica (Hradec Kralove); 2014; 57(3):97-104. PubMed ID: 25649364
[TBL] [Abstract][Full Text] [Related]
16. Familial Mediterranean fever without MEFV mutations: a case-control study.
Ben-Zvi I; Herskovizh C; Kukuy O; Kassel Y; Grossman C; Livneh A
Orphanet J Rare Dis; 2015 Mar; 10():34. PubMed ID: 25887307
[TBL] [Abstract][Full Text] [Related]
17. Intravenous colchicine treatment for six months: adjunctive therapy in familial Mediterranean fever (FMF) unresponsive to oral colchicine.
Rozenbaum M; Boulman N; Feld J; Avshovich N; Petrovich S; Elias M; Slobodin G; Rosner I
Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S105. PubMed ID: 19796546
[No Abstract] [Full Text] [Related]
18. Risk factors for subclinical inflammation in children with Familial Mediterranean fever.
Bayram MT; Çankaya T; Bora E; Kavukçu S; Ülgenalp A; Soylu A; Türkmen M
Rheumatol Int; 2015 Aug; 35(8):1393-8. PubMed ID: 25669438
[TBL] [Abstract][Full Text] [Related]
19. Colchicine treatment in children with familial Mediterranean fever: is it a risk factor for neuromyopathy?
Işıkay S; Yılmaz K; Yiğiter R; Balat A; Büyükçelik M
Pediatr Neurol; 2013 Dec; 49(6):417-9. PubMed ID: 24084143
[TBL] [Abstract][Full Text] [Related]
20. Can colchicine response be predicted in familial Mediterranean fever patients?
Özçakar ZB; Elhan AH; Yalçınkaya F
Rheumatology (Oxford); 2014 Oct; 53(10):1767-72. PubMed ID: 24764265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
